Compare Danaher Corporation (DHR) vs Virgin Galactic Holdings, Inc. (SPCE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Virgin Galactic Holdings, Inc. — how do they compare? Danaher Corporation trades at $205.66 (market cap $145.83B), while Virgin Galactic Holdings, Inc. trades at $3.27 (market cap $498.02M). The key difference: Danaher Corporation is far larger — about 292.8× Virgin Galactic Holdings, Inc.'s market cap, and Danaher Corporation pays a 0.77% dividend while Virgin Galactic Holdings, Inc. pays none. Which is the better fit depends on your goals.
| DHR | SPCE | |
|---|---|---|
Market Cap | $145.83B | $498.02M |
Sector | Health | Industrials |
52-Week High | $242.05 | $7.52 |
52-Week Low | $161.91 | $2.17 |
Enterprise Value | $168.04B | $597.87M |
Dividend Yield | 0.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $209.26, up 2.2% today, with strong technical momentum as the price sits above key support levels. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $1.92. Fundamentals show robust profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst sentiment is overwhelmingly positive with 69% buy ratings and a $202.33 consensus price target. Recent news highlights the acquisition of Masimo and new product launches in its biotechnology segment.
The outlook for DHR remains favorable driven by earnings beats and strategic acquisitions, but investors face risks from elevated valuation multiples and potential macroeconomic headwinds. The stock's current technical overbought condition suggests near-term consolidation may occur, yet long-term growth prospects in life sciences support a bullish stance. Key watch points include Q3 2026 earnings results and integration progress of recent acquisitions.
Virgin Galactic (SPCE) trades at $3.23, up 4.19% on the day, with a bullish technical signal from moving averages but overbought RSI levels near 91.63. The company continues to report significant losses, with a net income margin of -19,781.3% in 2025 and negative cash flow from operations of $240.14 million. Recent news highlights focus on upcoming Q2 2026 earnings and sector volatility amid SpaceX's market debut.
The outlook remains high-risk due to persistent unprofitability and cash burn, though recent quarterly EPS beats offer some optimism. Investment opportunity hinges on successful commercialization of space tourism, while risks include intense competition, funding needs, and execution challenges. Analyst sentiment is mixed with 29.41% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Virgin Galactic Holdings, Inc.
Virgin Galactic Holdings Inc. develops space vehicles. The Company designs exploration technology such as missiles, rockets, and other related equipment. Virgin Galactic Holdings serves customers in the United States.
Read more on SPCE →
